Humanized monoclonal antibodies and methods of use

Patent metadata

Field	Value
Publication number	US-9416169-B2
Application number	US-201514597044-A
Country	US
Kind code	B2
Filing date	Jan 14, 2015
Priority date	Dec 28, 2007
Publication date	Aug 16, 2016
Grant date	Aug 16, 2016

Abstract

The present invention comprises a humanized monoclonal antibody that binds to the chemokine receptor CCR4. This antibody is derived from Mab 1567 and recognizes the same epitope. Binding of the invented antibody to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.

First claim

What is claimed is:

1. A method of selectively killing a tumor cell comprising contacting said cell with a composition comprising a humanized monoclonal CC-chemokine receptor 4 (CCR4) antibody or fragment thereof, wherein said antibody has the following characteristics:
a. binds to CCR4 positive (CCR4+) cells but not CCR4 negative (CCR4−) cells;
b. decreases binding of a ligand or agonist to the CCR4 receptor; and wherein said antibody comprises
i. a heavy chain variable region encoded by the nucleic acid sequence comprising:
CAGGTGCAGCTGGTGCAGAGCGGAGCCGAGGTGAAGAAGCCTG GAGCTTCCGTCAAGGTGTCCTGCAAGGCCAGCGGCTACACCTTC GCCAGCTACTACATGCACTGGATGCGGCAGGCACCTGGACAGG GCCTCGAATGGATCGGCTGGATCAACCCCGGCAACGTGAACAC CAAGTACAACGAGAAGTTCAAGGGCAGGGCCACCCTGACCGTG GACACCAGCACCAACACCGCCTACATGGAACTGAGCAGCCTGC GGAGCGAGGACACCGCCGTGTACTACTGCGCCAGAAGCACCTA CTACCGGCCCCTGGACTACTGGGGCCAGGGCACCCTGGTGACC GTGAGCAGC (SEQ ID NO:1); or

ii. a heavy chain variable region comprising the amino acid sequence:
QVQLVQSGAEVKKPGASVKVSCKASGYTFASYYMHWMRQAPG QGLEWIGWINPGNVNTKYNEKFKGRATLTVDTSTNTAYMELS SL RSEDTAVYYCARS TYYRPLDYWGQGTLVTVSS (SEQ ID NO:2); and

iii. a light chain variable region encoded by the nucleic acid sequence comprising:
GACATCGTGATGACCCAGAGCCCCGACAGCCTGGCCGTGAGCC TGGGCGAGCGGGCCACCATCAACTGCAAGAGCAGCCAGAGCA TCCTGTACAGCAGCAACCAGAAGAACTACCTGGCCTGGTATCA GCAGAAGCCCGGCCAGAGCCCCAAGCTGCTGATCTACTGGGCC AGCACCCGGGAGAGCGGCGTGCCCGACCGGTTTAGCGGCAGC GGCTCCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGG CCGAGGACGTGGCCGTGTACTACTGCCACCAGTACCTGAGCAG CTACACCTTCGGCCAGGGCACAAAGCTGGAAATCAAG (SEQID NO:3); or

iv. a light chain variable region comprising the amino acid sequence:
DIVMTQSPDSLAVSLGERATINCKSSQSILYSSNQKNYLAWYQQKPG QSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC HQYLSSYTFGQGTKLEIK (SEQ ID NO:4).

2. The method of claim 1 , wherein said selective killing occurs by antibody-dependent cellular toxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody dependent cellular phagocytosis (ADCP).

3. The method of claim 1 , wherein said tumor cell expresses CCR4.

4. The method of claim 1 , wherein said tumor cell is a T-cell.

5. A method of decreasing suppressor T-cell activity comprising contacting said cell with a composition comprising a humanized monoclonal CC-chemokine receptor 4 (CCR4) antibody or fragment thereof, wherein said antibody has the following characteristics:
a. binds to CCR4 positive (CCR4+) cells but not CCR4 negative (CCR4−) cells;
b. decreases binding of a ligand or agonist to the CCR4 receptor; and wherein said antibody comprises
i. a heavy chain variable region encoded by the nucleic acid sequence comprising:
CAGGTGCAGCTGGTGCAGAGCGGAGCCGAGGTGAAGAAGCCTG GAGCTTCCGTCAAGGTGTCCTGCAAGGCCAGCGGCTACACCTTC GCCAGCTACTACATGCACTGGATGCGGCAGGCACCTGGACAGG GCCTCGAATGGATCGGCTGGATCAACCCCGGCAACGTGAACAC CAAGTACAACGAGAAGTTCAAGGGCAGGGCCACCCTGACCGTG GACACCAGCACCAACACCGCCTACATGGAACTGAGCAGCCTGC GGAGCGAGGACACCGCCGTGTACTACTGCGCCAGAAGCACCTA CTACCGGCCCCTGGACTACTGGGGCCAGGGCACCCTGGTGACC GTGAGCAGC (SEQ ID NO:1); or

ii. a heavy chain variable region comprising the amino acid sequence:
QVQLVQSGAEVKKPGASVKVSCKASGYTFASYYMHWMRQAPG QGLEWIGWINPGNVNTKYNEKFKGRATLTVDTSTNTAYMELS SL RSEDTAVYYCARS TYYRPLDYWGQGTLVTVSS (SEQ ID NO:2); and

iii. a light chain variable region encoded by the nucleic acid sequence comprising:
GACATCGTGATGACCCAGAGCCCCGACAGCCTGGCCGTGAGCC TGGGCGAGCGGGCCACCATCAACTGCAAGAGCAGCCAGAGCA TCCTGTACAGCAGCAACCAGAAGAACTACCTGGCCTGGTATCA GCAGAAGCCCGGCCAGAGCCCCAAGCTGCTGATCTACTGGGCC AGCACCCGGGAGAGCGGCGTGCCCGACCGGTTTAGCGGCAGC GGCTCCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGG CCGAGGACGTGGCCGTGTACTACTGCCACCAGTACCTGAGCAG CTACACCTTCGGCCAGGGCACAAAGCTGGAAATCAAG (SEQID NO:3); or

iv. a light chain variable region comprising the amino acid sequence:
DIVMTQSPDSLAVSLGERATINCKSSQSILYSSNQKNYLAWYQQKPG QSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC HQYLSSYTFGQGTKLEIK (SEQ ID NO:4).

6. A method of augmenting an immune response to an antigen comprising contacting said cell with a composition comprising a humanized monoclonal CC-chemokine receptor 4 (CCR4) antibody or fragment thereof, wherein said antibody has the following characteristics:
a. binds to CCR4 positive (CCR4+) cells but not CCR4 negative (CCR4−) cells;
b. decreases binding of a ligand or agonist to the CCR4 receptor; and wherein said antibody comprises
i. a heavy chain variable region encoded by the nucleic acid sequence comprising:
CAGGTGCAGCTGGTGCAGAGCGGAGCCGAGGTGAAGAAGCCTG GAGCTTCCGTCAAGGTGTCCTGCAAGGCCAGCGGCTACACCTTC GCCAGCTACTACATGCACTGGATGCGGCAGGCACCTGGACAGG GCCTCGAATGGATCGGCTGGATCAACCCCGGCAACGTGAACAC CAAGTACAACGAGAAGTTCAAGGGCAGGGCCACCCTGACCGTG GACACCAGCACCAACACCGCCTACATGGAACTGAGCAGCCTGC GGAGCGAGGACACCGCCGTGTACTACTGCGCCAGAAGCACCTA CTACCGGCCCCTGGACTACTGGGGCCAGGGCACCCTGGTGACC GTGAGCAGC (SEQ ID NO:1); or

ii. a heavy chain variable region comprising the amino acid sequence:
QVQLVQSGAEVKKPGASVKVSCKASGYTFASYYMHWMRQAPG QGLEWIGWINPGNVNTKYNEKFKGRATLTVDTSTNTAYMELS SL RSEDTAVYYCARS TYYRPLDYWGQGTLVTVSS (SEQ ID NO:2); and

iii. a light chain variable region encoded by the nucleic acid sequence comprising:
GACATCGTGATGACCCAGAGCCCCGACAGCCTGGCCGTGAGCC TGGGCGAGCGGGCCACCATCAACTGCAAGAGCAGCCAGAGCA TCCTGTACAGCAGCAACCAGAAGAACTACCTGGCCTGGTATCA GCAGAAGCCCGGCCAGAGCCCCAAGCTGCTGATCTACTGGGCC AGCACCCGGGAGAGCGGCGTGCCCGACCGGTTTAGCGGCAGC GGCTCCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGG CCGAGGACGTGGCCGTGTACTACTGCCACCAGTACCTGAGCAG CTACACCTTCGGCCAGGGCACAAAGCTGGAAATCAAG (SEQID NO:3); or

iv. a light chain variable region comprising the amino acid sequence:
DIVMTQSPDSLAVSLGERATINCKSSQSILYSSNQKNYLAWYQQKPG QSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC HQYLSSYTFGQGTKLEIK (SEQ ID NO:4).

7. The method of claim 6 , wherein said antigen is a viral antigen, a bacterial antigen or a tumor associated antigen.

8. The method of claim 7 , wherein said viral antigen is HIV.

9. The method of claim 6 , wherein said antibody is administered prior to or after exposure to the antigen.

10. The method of claim 6 , wherein said administration of said antibody causes an increase in antigen specific T cell activity.

11. The method of claim 10 , wherein said T-cell is an effector T-cell.

12. A method of increasing vaccine efficiency comprising administering to a subject a vaccine and a composition comprising a humanized monoclonal CC-chemokine receptor 4 (CCR4) antibody or fragment thereof, wherein said antibody has the following characteristics:
a. binds to CCR4 positive (CCR4+) cells but not CCR4 negative (CCR4−) cells;
b. decreases binding of a ligand or agonist to the CCR4 receptor; and wherein said antibody comprises
i. a heavy chain variable region encoded by the nucleic acid sequence comprising:
CAGGTGCAGCTGGTGCAGAGCGGAGCCGAGGTGAAGAAGCCTG GAGCTTCCGTCAAGGTGTCCTGCAAGGCCAGCGGCTACACCTTC GCCAGCTACTACATGCACTGGATGCGGCAGGCACCTGGACAGG GCCTCGAATGGATCGGCTGGATCAACCCCGGCAACGTGAACAC CAAGTACAACGAGAAGTTCAAGGGCAGGGCCACCCTGACCGTG GACACCAGCACCAACACCGCCTACATGGAACTGAGCAGCCTGC GGAGCGAGGACACCGCCGTGTACTACTGCGCCAGAAGCACCTA CTACCGGCCCCTGGACTACTGGGGCCAGGGCACCCTGGTGACC GTGAGCAGC (SEQ ID NO:1); or

ii. a heavy chain variable region comprising the amino acid sequence:
QVQLVQSGAEVKKPGASVKVSCKASGYTFASYYMHWMRQAPG QGLEWIGWINPGNVNTKYNEKFKGRATLTVDTSTNTAYMELS SL RSEDTAVYYCARS TYYRPLDYWGQGTLVTVSS (SEQ ID NO:2); and

iii. a light chain variable region encoded by the nucleic acid sequence comprising:
GACATCGTGATGACCCAGAGCCCCGACAGCCTGGCCGTGAGCC TGGGCGAGCGGGCCACCATCAACTGCAAGAGCAGCCAGAGCA TCCTGTACAGCAGCAACCAGAAGAACTACCTGGCCTGGTATCA GCAGAAGCCCGGCCAGAGCCCCAAGCTGCTGATCTACTGGGCC AGCACCCGGGAGAGCGGCGTGCCCGACCGGTTTAGCGGCAGC GGCTCCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGG CCGAGGACGTGGCCGTGTACTACTGCCACCAGTACCTGAGCAG CTACACCTTCGGCCAGGGCACAAAGCTGGAAATCAAG (SEQID NO:3

Assignees

• Dana Farber Cancer Inst Inc
• The Brigham And Women'S Hospital

Inventors

• Marasco Wayne
• Sui Jianhua
• Zhu Quan
• Kupper Thomas

Classifications

• A61P37/04

  Immunostimulants · CPC title

• A61P31/18

  for HIV · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P31/12

  Antivirals · CPC title